Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD ...

Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.

COPD (Chronic Obstructive Pulmonary Disease) is a lung disease that causes breathing difficulties, chronic cough, and mucus.

The National Medical Products Administration approved Dupixent as an add-on maintenance treatment for adults with ...

Changes in people’s voices recoded on a smartphone can signal a serious flare up in symptoms of chronic obstructive pulmonary ...

Lung disease affects around 1 in 7 older persons, making it a serious health risk. Among persons 60 years of age and older, ...

The approval makes COPD the sixth indication for the blockbuster treatment and makes Dupixent the first available biologic for the condition. As per a 27 September press announcement, Dupixent ...

Chronic obstructive lung disease, also known as chronic obstructive pulmonary disease (COPD), is a general term for a group ...

The voice of people with chronic obstructive pulmonary disease may become more pitched and breathy or hoarse at the onset of ...

China NMPA approves Sanofi & Regeneron’s Dupixent as an add-on maintenance treatment for adults with uncontrolled COPD: Paris Monday, September 30, 2024, 11:00 Hrs [IST] The Nat ...